Remove Immunity Remove Nursing Homes Remove Vaccines
article thumbnail

Lilly’s antibody for COVID-19 protection starts nursing home trial

pharmaphorum

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The post Lilly’s antibody for COVID-19 protection starts nursing home trial appeared first on.

article thumbnail

Drug Prevents Coronavirus Infection in Nursing Homes, Maker Claims

NY Times

A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly Claims Drug Prevents Coronavirus Infection in Nursing Homes

NY Times

A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.

article thumbnail

F.D.A. Clears Moderna's Covid Vaccine

NY Times

The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.

Vaccines 105
article thumbnail

The Use of Antipsychotic Drugs in Nursing Homes

NY Times

A professor, a psychiatrist and a nurse react to a Times investigation. Also: A modern Civil War; a more confident child.

article thumbnail

The End Is Near: Impact of the Public Health Emergency Expiration

Integra X Files

The COVID-19 PHE suspended various training requirements, suspended personal visit requirements for physicians and other providers, allowed telehealth visits, and made vaccines and treatments widely available. Beginning in 2024, the administration fee for COVID-19 immunizations will be in line with other Medicare Part B vaccines.

article thumbnail

Coronavirus pharma news roundup – 07/08/20

pharmaphorum

The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1 Gillead lost $3.3bn in Q2, with the company blaming COVID-19 and its acquisition of immune-oncology company Forty Seven for the fall.